Financial Lp Hrt Sells 49,710 Shares of Onconetix (NASDAQ:ONCO) Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt sold 49,710 shares of Onconetix stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $0.69, for a total value of $34,299.90. Following the transaction, the insider owned 33,649 shares in the company, valued at approximately $23,217.81. This trade represents a 59.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The shares were sold at an average price of $0.73, for a total value of $39,322.91.
• On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The shares were sold at an average price of $0.75, for a total value of $70,846.50.
• On Friday, April 17th, Financial Lp Hrt purchased 34,636 shares of Onconetix stock. The shares were purchased at an average price of $0.73 per share, for a total transaction of $25,284.28.
• On Wednesday, April 15th, Financial Lp Hrt purchased 92,554 shares of Onconetix stock. The shares were purchased at an average price of $0.76 per share, for a total transaction of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt purchased 74,350 shares of Onconetix stock. The shares were purchased at an average price of $0.77 per share, for a total transaction of $57,249.50.

Onconetix Stock Performance

Shares of ONCO stock opened at $0.67 on Friday. Onconetix, Inc. has a 1 year low of $0.65 and a 1 year high of $74.29. The stock has a market cap of $442,200.00, a PE ratio of 0.00 and a beta of 3.63. The business’s fifty day moving average is $2.35 and its 200-day moving average is $8.40.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Citadel Advisors LLC purchased a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 23.89% of the company’s stock.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.